Korean J Pediatr Hematol Oncol.  2000 Oct;7(2):242-248.

A Trial Use of Prophylactic Low-Dose Lipo PGE1 (Eglandin) for the Prevention of Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation in Children with Hematologic Malignancies

• Cho B
• Sung IK
• Kim DW
• Lee HJ
• Kim SY
• Chung NG
• Kim CC
• Kim HK

Abstract

PURPOSE: In this study we tested the hypothesis that vasodilatation and antithrombogenic effect in damaged vessels using low-dose Lipo PGE1 might result in increased sinusoidal blood flow and in decreased obstruction and minimize the incidence or severity of hepatic veno-occlusive disease (VOD). METHPDS: Children underwent hematopoietic stem cell transplantation for hematologic malignancies were enrolled in this study. Lipo PGE1 was begun one day prior to the start of conditioning to day 30 after stem cell transplantation in continuous intravenous infusion at a dose of 1 mug/kg/day (0.042 mug/ kg/hr). We evaluate the incidence and severity of hepatic VOD and the toxicity of Lipo PGE1.
RESULTS
From November 1999 to Jun 2000, 20 patients (M:F=15:5, median age 5 years) underwent hematopoietic stem cell (5 matched sibling bone marrow, 4 autologous bone marrow, 8 unrelated bone marrow, 3 unrelated cord blood) transplantation for hematologic malignancies (9 ALL, 8 AML, 3 CML) were enrolled in this study. There was no occurrence of VOD within 30 day of transplant. Only one out of 20 patients was diagnosed as delayed VOD, easily controlled moderate form, on post-transplant day 58. There was no toxicity attributed to Lipo PGE1.
CONCLUSION
This study suggests that prophylactic low-dose Lipo PGE1 treatment may decrease the incidence of VOD in patients treated for hematologic malignancies by hematopoietic stem cell transplantation.

Keyword

Hepatic veno-occlusive disease; VOD; Prostaglandine E1; Lipo Prostaglandine E1; Eglandin; Stem cell transplantation

MeSH Terms

Alprostadil*
Bone Marrow
Child
Hematologic Neoplasms*
Hematopoietic Stem Cell Transplantation*
Hematopoietic Stem Cells*
Hepatic Veno-Occlusive Disease*
Humans
Incidence
Infusions, Intravenous
Siblings
Stem Cell Transplantation
Vasodilation
Alprostadil